Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: gcrispin who wrote (715)	8/3/2005 7:56:29 PM
From: keokalani'nui	Respond to of 946

Bailing out at CTIC. Of course without Trisenox, what's to market? AnorMED Inc. is pleased to announce that Mr. Mark Levonyak has joined AnorMED as the Vice President, Marketing. He has over 20 years of experience in pharmaceutical marketing, sales and product launches. Previously with Cell Therapeutics ("CTI") for five years, Mr. Levonyak was responsible for driving the performance of CTI's oncology and hematology product portfolio including TRISENOX(R), XYOTAX(TM), Pixantrone and CT-2106. At CTI, his experience and responsibilities as Vice President, Marketing, spanned product management, strategic planning, and market research. Most recently, he led the transition of TRISENOX from its original niche market of refractory acute promyelocytic leukemia, and annual sales of US$5 million, to peak sales of US$ 30 million, by launching an expansion of brand awareness into other hematologic malignancies. Prior to CTI, Mr. Levonyak spent 15 years in sales of oncology products with SmithKline Beecham Pharmaceuticals in the U.S. While there, Mr. Levonyak launched the SmithKline Beecham commercial oncology team including sales, national accounts, reimbursement, and medical affairs programs in preparation for the launch of the oncology product Hycamtin.